OCID 2987: A Novel, Chemically Distinct Orally Active PDE4 Inhibitor

Vishwakarma, Sandeep Kumar; Saxena, Sanjai; Honnegowda, Srinivasa; Ganesan, K.; Ahamed, Fakrudeen Ali; Surendran, Naveen; Narayanan, Shridhar; Rajagopal, Senthilkumar; Balasubramaniam, Gowrie

doi:10.1016/j.jaci.2009.12.226

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[200] The company's own internal discovery efforts had ab road therapeuticf ocus, covering infectious diseases, inflammation, pain, oncology,m etabolic disorders, and CNS diseases. OCID-2987, [197,201] aP DE4i nhibitor for the treatment of inflammatoryd isorders such as COPD, completed successfully Phase 1s tudies in Europei n2 012, and OCID-4681 29, [202,203] ah istoned eacetylase( HDAC) inhibitor for cancerh ad received approvali n2 011f or Phase 1s tudies for solid tumors in India, but we assume both have been abandoned, as cancer and inflammation are not mentioned in the company's latest annual reports. [197] Twoa dditional compounds were abandoned at the preclinical stage:O CID-5005,aSTAT-3/IL-6 inhibitor foro ncology,a nd au nnamed Th1/Th2 cytokines ynthesis inhibitor for inflammation (Supporting Information Ta ble 2a, entries [134][135][136][137][138].…”

Section: Initiation Of Drug Discovery At Large Pharmaceutical Companiesmentioning

confidence: 99%

“…Rhizen Pharmaceuticals S.A. was incorporated in Switzerland, with the aim to develop and partner compounds originating from Incozen,abiotechc ompany founded in 2008 in Hyderabad to discovern ovel treatments for oncology and inflammation (Supporting Information Ta ble 6a, entries [199][200][201][202][203][204]. [322,323] Both companies were established with funding from Alembic Ltd. (see above).…”

Section: The Rise Of Drug Discovery At Biotechnology Companiesmentioning

confidence: 99%

See 1 more Smart Citation

The Drug Discovery and Development Industry in India—Two Decades of Proprietary Small‐Molecule R&D

Differding¹

2017

ChemMedChem

View full text Add to dashboard Cite

This review provides a comprehensive survey of proprietary drug discovery and development efforts performed by Indian companies between 1994 and mid‐2016. It is based on the identification and detailed analysis of pharmaceutical, biotechnology, and contract research companies active in proprietary new chemical entity (NCE) research and development (R&D) in India. Information on preclinical and clinical development compounds was collected by company, therapeutic indication, mode of action, target class, and development status. The analysis focuses on the overall pipeline and its evolution over two decades, contributions by type of company, therapeutic focus, attrition rates, and contribution to Western pharmaceutical pipelines through licensing agreements. This comprehensive analysis is the first of its kind, and, in our view, represents a significant contribution to the understanding of the current state of the drug discovery and development industry in India.

show abstract

Section: Initiation Of Drug Discovery At Large Pharmaceutical Companiesmentioning

confidence: 99%

Section: The Rise Of Drug Discovery At Biotechnology Companiesmentioning

confidence: 99%